HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

5-Bromotetrandrine enhances the sensitivity of doxorubicin-induced apoptosis in intrinsic resistant human hepatic cancer Bel7402 cells.

Abstract
5-Bromotetrandrine (BrTet) was shown to overcome multi-drug resistance (MDR) in vitro and in vivo by inhibiting the overexpression and efflux function of P-glycoprotein in our previous study. The purpose of the present study was to evaluate the effect of BrTet on the sensitivity of doxorubicin (Dox) induced apoptosis in intrinsic resistant human hepatic cancer Bel7402 cells. The cells were treated with non-toxic concentrations of BrTet (1 microM, 2 microM, 4 microM) or the positive control drug verapamil (Vrp) (10 microM) for 24h followed by a low dose Dox (3 microM) for 24 h. The results showed that BrTet pretreatment followed by Dox led to typical apoptotic characters as indicated by morphologic changes, DNA fragmentation and changes in cell cycle, while the same dose of BrTet, Vrp and Dox alone did not induce apoptosis in Bel7402 cells. In addition, the pretreatment of BrTet or Vrp followed by Dox induced activation of caspase-3, release of cytochrome c and AIF from mitochondria into cytosol, loss of mitochondrial transmembrane potential (DeltaPsi(m)) and elevation of Bax/Bcl-2 ratio, with no effect on activation of caspase-8 and the expression of Fas/FasL. In conclusion, BrTet pretreatment enhanced the sensitivity of Dox to induce apoptosis by causing loss of DeltaPsi(m) and elevating the ratio of Bax/Bcl-2, eventually activated mitochondrial apoptotic pathway. These findings further support the potential of BrTet to be used in clinical trail of cancer treatment.
AuthorsXiao Dong Liu, Hua Sun, Geng Tao Liu
JournalCancer letters (Cancer Lett) Vol. 292 Issue 1 Pg. 24-31 (Jun 01 2010) ISSN: 1872-7980 [Electronic] Ireland
PMID19962232 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
CopyrightCopyright (c) 2009 Elsevier Ireland Ltd. All rights reserved.
Chemical References
  • Benzylisoquinolines
  • Receptors, Death Domain
  • bromotetrandrine
  • Doxorubicin
  • Verapamil
  • Caspase 3
Topics
  • Apoptosis (drug effects)
  • Benzylisoquinolines (administration & dosage, pharmacology)
  • Caspase 3 (biosynthesis)
  • Cell Line, Tumor
  • Doxorubicin (administration & dosage, pharmacology)
  • Drug Resistance, Multiple (drug effects)
  • Drug Synergism
  • Enzyme Activation
  • Humans
  • Liver Neoplasms (drug therapy)
  • Receptors, Death Domain (metabolism)
  • Verapamil (pharmacology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: